Graduate Ventures backs women's health startup decipHER in pre-seed round
What's the deal? Graduate VenturesDealroom has a profile for this one. Try Dealroom → has backed decipHERDealroom has a profile for this one. Try Dealroom →, a women's health startup building an AI platform to spot peripartum and postpartum depression before symptoms turn into a crisis.
The pre-seed investment, announced in June 2026, supports a tool that combines questionnaire data with biological markers from blood samples taken during and after pregnancy.
The platform tracks hormones, immune markers, metabolites, and genetic information over time. It then flags biological signatures linked to depression risk and turns them into care recommendations.
Why now? Maternal mental healthcare is still largely reactive, treating women only after symptoms appear.
Postpartum depression affects an estimated 10–20% of mothers worldwide. With roughly 130 million births globally each year, the unmet need is vast.
DecipHER aims to become the missing diagnostic layer, enabling earlier intervention and more personalised care.
What could go wrong? Diagnostic tools built on biological markers face a long road of clinical validation before they reach patients.
The startup must prove its signatures reliably predict risk, then navigate regulation and clinical adoption — no small task for an early-stage company.
The signal: Women's health remains a significantly underserved market, and investors are increasingly moving to close the gap.
DecipHER reflects a broader shift toward predictive, data-driven care, betting that AI can turn maternal mental health from reactive treatment into early prevention.
The company is led by founder Amy FitzPatrick, a biologist with 30 years of healthcare experience, joined by Carolyn Keating and advisors from Erasmus MC, Amsterdam UMC, OLVG, and the University of Iowa.
Read more: Graduate Ventures
